Health & Safety Industry Today
Cell Based Immunotherapy Market to Surpass USD 10.54 billion by 2030 Driven by Rapid Advances in CAR-T Cell Therapies and Targeted Oncology Treatments
Introduction
The cell-based immunotherapy market is valued at USD 5.24 billion in 2025 and is forecasted to reach USD 10.54 billion by 2030, yielding a 14.98% CAGR. The market’s growth is underpinned by increased R&D in personalized medicine, higher clinical success rates of cell-based therapeutics, and an expanding global pipeline for CAR-T and NK cell therapies.
Biopharmaceutical companies are investing heavily in advanced cell processing technologies, while regulatory agencies are introducing adaptive approval frameworks to fast-track novel therapies. The demand for curative and minimally invasive treatment alternatives continues to shape investment priorities within the cell based immunotherapy market analysis.
Key Trends
- Rapid Advances in Gene-Editing and Viral-Vector Engineering
- Surging Cancer Prevalence and Earlier-Line Use Approvals
- Expanding Reimbursement Frameworks for CAR-T Launches
- Big-Pharma M&A, Licensing and Capacity Build-Outs
- Complex, Fragile Supply-Chain and Talent Shortages
- Cytokine-Release-Syndrome Management Liability Risk
Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights:
Market Segmentation
By Therapy
- Autologous
- Allogeneic
By Primary Indication
- B-cell Malignancies
- Prostate Cancer
- Renal Cell Carcinoma
- Liver Cancer
- Other Indications
Geography Analysis
North American healthcare providers continue to sustain strong treatment volumes supported by reliable reimbursement systems and an established referral base. Even with workforce challenges, regional expansion and favorable payment adjustments maintain steady market growth. Research institutions are diversifying beyond oncology into new therapeutic areas, creating broader opportunities.
In Asia-Pacific, supportive policies and local production capacity drive affordability and access, while countries such as China and India expand their manufacturing and clinical infrastructure. However, gaps in accreditation and supply chain dependence persist.
Europe shows balanced progress through regulatory alignment and outcome-based payment models. Localized production and academic collaborations help streamline costs, though pricing constraints continue to influence wider adoption across the region.
Explore Our Full Library of Healthcare Research Industry Reports - https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=Industrytoday.co.uk
Key Players
Leading companies in the cell-based immunotherapy market include Novartis AG, Gilead Sciences, Inc. (Kite Pharma), Bristol-Myers Squibb Co., Johnson & Johnson (Janssen), and Pfizer Inc. These major players dominate the competitive landscape through extensive clinical pipelines, advanced CAR-T therapy portfolios, and strategic collaborations aimed at expanding access to personalized cancer treatment and next-generation immuno-oncology solutions.
Trending Reports
About Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking actionable market insights. With 550+ domain experts and specialists across 150+ countries, we deliver comprehensive syndicated and custom research across industries such as aerospace, agriculture, chemicals, consumer goods, energy, healthcare, and many more, helping organizations make informed decisions and achieve strategic goals.
For any inquiries or to access the full report, please contact:
https://www.mordorintelligence.com/
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
